6th World Congress on Leishmaniasis
18 May
Parallel Session
Cutaneous leishmaniasis and pipeline drugs
Chair: Max Grögl, US Naval Medical Research Unit, No 6, Lima, Peru
Co-chair: Elizabeth Valdivieso, Universidad Central Caracas, Venezuela
| Current recommendations for treating CL worldwide Afif Bensalah, Arabian Golf University, Bahrein |
| CL treatment: clinical developments Byron Arana, DNDi, Geneva, Switzerland |
| CL R&D pipeline Charles Mowbray, DNDi, Geneva, Switzerland |
| Harmonized clinical trial methodologies for CL Piero Olliaro, WHO/TDR, Geneva, Switzerland |
Oral Communications Session
Clinical and experimental immunopathology and pathogenesis
| Macrophage activation marker neopterin as a pharmodynamic biomarker in visceral leishmaniasis Kip AE, Musa A, Khalil E, Wasunna M, Alves F, Dorlo TPC |
Consensus Symposium
Roadmap for cutaneous leishmaniasis drugs
Conducted by:
Simon Croft, London School of Hygiene and Tropical Medicine, UK
Byron Arana, DNDi, Geneva, Switzerland
|
Where are we for cutaneous leishmaniasis R&D? Simon Croft, LSHTM and Byron Arana, DNDi, Geneva, Switzerland |
|
So what do we need? Charlie Mowbray, DNDi, Geneva, Switzerland |
|
How do we do it? Katrien van Bocxlaer, LSHTM, UK and Sima Rafati, Institut Pasteur, France |
Satellite Symposium
Communication and neglected tropical diseases: an illustration with leishmaniasis and other NTDs
Organized by Mundo Sano & DNDi and sponsored by Mundo Sano
Chair: Irene Tato, Mundo Sano
Co-chair: Jean François Alesandrini, DNDi, Geneva, Switzerland
Participants:
- Emilio de Benito, El País, Chair of ANIS, Spanish Association of Health Journalists
- Antonio Calvo Roy, Chair of the AECC, Spanish Association of Scientific Communicators
- Talha Burki, The Lancet, UK
- Verah Okeyo, Daily Nation, Kenya
- Nora Bär, La Nación, Argentina
- Franziska Badenschier, European Science Journalists, Germany
Poster Presentations
|
Comparative evaluation of diagnosis of post kala-azar dermal leishmaniasis by qPCR, microscopy and rK39 in cohort of Kala Azar patients treated with three new treatment regimens Goyal V, Radi Das VN, Pandey K,Rijal S, Alves F, Das P, Alvar J |
|
Treatment of visceral leishmaniasis patients outside clinical trials; the case of the Leishmaniasis East Africa Platform Malongo J, Kimutai R, Alves F, Musa B, Diro E, Riongoita M, Sagaki P, Okello L, Mudawi AM, Khali E, Hailu A, Mbui J, Alvar J, Wasunna M |
